Secukinumab, ixekizumab, bimekizumab and brodalumab for the treatment of psoriasis and psoriatic arthritis

In recent years, the role of interleukin-17 (IL-17) in orchestrating and manipulating proinflammatory immune responses has received special attention. It has become apparent from murine studies and clini-cal trials that due to its inhibitory effect on immuno-regulation and its stimulatory action on promoting proinflammatory responses, IL-17 is an ideal cytokine to target for drug development, in order to cease its induction or eliminate IL-17-producing cells of any kind. Several monoclonal antibodies have been developed and tested as potent inhibitors of IL-17 in various inflammatory diseases. This review summarizes data from relevant clinical trials on recent developments of the application of inhibitors of IL-17 in psoriasis and psoriatic arthritis, namely secukinumab, ixekizumab, bimekizumab and brodalumab.

Automated summary

In recent years, there has been significant interest in the role of interleukin-17 (IL-17) in promoting proinflammatory immune responses. IL-17, due to its inhibitory effect on immuno-regulation and stimulatory action on inflammation, has become a target for drug development. This review discusses the recent developments in IL-17 inhibitors, such as secukinumab, ixekizumab, bimekizumab, and brodalumab, for the treatment of psoriasis and psoriatic arthritis.